Yahoo Finance Top Ranked Momentum Stocks to Buy for May 5th
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 5th:
Zynex, Inc. (ZYXI): This company that designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 14.3% over the last 60 days.
Zynex Inc. Price and Consensus
Zynex Inc. price-consensus-chart | Zynex Inc. Quote
Zynex’s shares gained 84.1% over the last one month compared with the S&P 500 growth 15.7%. The company possesses a Momentum Score of A.
Zynex Inc. Price
Zynex Inc. price | Zynex Inc. Quote
Pluralsight, Inc. (PS): This company that provides a technology skill development solutions has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 18.4% over the last 60 days.
Pluralsight, Inc. Price and Consensus
Pluralsight, Inc. price-consensus-chart | Pluralsight, Inc. Quote
Pluralsight’s shares gained 58.5% over the last one month. The company possesses a Momentum Score of A.
Pluralsight, Inc. Price
Pluralsight, Inc. price | Pluralsight, Inc. Quote
Gold Fields Limited (GFI): This company that operates as a gold producer with reserves and resources has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.8% over the last 60 days.
Gold Fields Limited Price and Consensus
Gold Fields Limited price-consensus-chart | Gold Fields Limited Quote
Gold Fields’ shares gained 47.4% over the last one month. The company possesses a Momentum Score of A.
Gold Fields Limited Price
Gold Fields Limited price | Gold Fields Limited Quote
Axovant Gene Therapies Ltd. (AXGT): This clinical-stage gene therapy company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.4% over the last 60 days.
Axovant Sciences Ltd. Price and Consensus
Axovant Sciences Ltd. price-consensus-chart | Axovant Sciences Ltd. Quote
Axovant Gene Therapies’ shares gained 28.1% over the last one month. The company possesses a Momentum Score of A.
Axovant Sciences Ltd. Price
Axovant Sciences Ltd. price | Axovant Sciences Ltd. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Zynex Inc. (ZYXI) : Free Stock Analysis Report
Pluralsight, Inc. (PS) : Free Stock Analysis Report
Gold Fields Limited (GFI) : Free Stock Analysis Report
Axovant Sciences Ltd. (AXGT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
